vericel
-
Sports Medicine
Vericel Announces Expansion of MACI Coverage by UnitedHealthcare to Include Patella and Multiple Cartilage Defects in the Knee
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine…
Read More » -
Sports Medicine
Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years
CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports…
Read More » -
Financial
Vericel Reports Second-Quarter 2017 Financial Results
CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for…
Read More » -
Sports Medicine
Vericel to Host Symposium on MACI Implant for Treating Articular Cartilage Defects in the Knee at AOSSM 2017 Annual Meeting
CAMBRIDGE, Mass., July 13, 2017 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for…
Read More » -
Financial
Vericel Reports First-Quarter 2017 Financial Results
CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for…
Read More » -
Extremities
Vericel Announces First MACI Implant in the United States for the Treatment of Symptomatic Cartilage Defects of the Knee
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for…
Read More » -
Financial
Vericel Corporation Prices $17 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 16, 2016 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for…
Read More » -
Financial
Vericel Reports Third-Quarter 2016 Financial Results
CAMBRIDGE, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for…
Read More » -
Financial
Vericel Reports Second-Quarter 2016 Financial Results
CAMBRIDGE, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for…
Read More » -
Financial
Vericel Reports First-Quarter 2016 Financial Results
CAMBRIDGE, Mass., May 10, 2016 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for…
Read More » -
Biologics
Aastrom Biosciences Changes Name to Vericel Corporation
Headquarters moved to Cambridge, Mass.; New ticker symbol: VCEL CAMBRIDGE, Mass., November 24, 2014 (GLOBE NEWSWIRE) – Aastrom Biosciences, Inc.…
Read More » -
Biologics
Aastrom Biosciences Announces Plans to Change Name to Vericel Corporation and Move Headquarters to Cambridge, Massachusetts
ANN ARBOR, Mich., Oct. 9, 2014 (GLOBE NEWSWIRE) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular…
Read More »